The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Surgical Oncology
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1336539
Duodenal ampulla neuroendocrine tumor and gastrointestinal stromal tumors in a case of neurofibromatosis type 1: a case report
Provisionally accepted- 1 Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
- 2 Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, Zhengzhou, China
- 3 Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan Province, China
Neurofibromatosis type 1 (NF-1) is commonly associated with a variety of rare tumors. However, no case of multiple gastric gastrointestinal stromal tumors (GISTs) or duodenal ampulla neuroendocrine tumors (NETs) with multiple liver metastases in an NF-1 patient has yet been reported. We here describe a case of a 55-year-old female patient with NF-1 whose serum proGRP levels were elevated. Gastrointestinal endoscopy and biopsy showed duodenal papilla occupying space, and the pathological diagnosis turned out to be neuroendocrine tumors (NETs). During surgical exploration, multiple tumors were found on the serosal surface of the stomach and numerous miliary metastases in the liver. Following histopathological examination, it was determined that the liver metastases were neurofibromatosis type 1 (NF-1) and the tumors in the gastric wall were gastrointestinal stromal tumors (GISTs).The patient benefited from targeted therapy, and had an uneventful hospital stay. In this case, we emphasize treating patients of neurofibromatosis type 1 who exhibit abdominal symptoms with a high degree of clinical suspicion and performing thorough evaluations to rule out multiple tumors.
Keywords: case report, neurofibromatosis type 1, Gastrointestinal Stromal Tumors, Neuroendocrine Tumors, surufatinib
Received: 10 Nov 2023; Accepted: 29 Aug 2024.
Copyright: © 2024 Zhang, Zheng, Chen, Meng, Qiu, Zhang, Han, Zhuang and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Peng Zheng, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Jiaqi Chen, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Bo Meng, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Dapeng Qiu, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Feng Han, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China
Hao Zhuang, Department of Hepatobiliopancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou 450008, Zhengzhou, China
Lu Zheng, Department of Medical Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.